Fennec Pharmaceuticals (FENC) Operating Leases (2023 - 2024)
Fennec Pharmaceuticals' (FENC) quarterly Operating Leases came in at $2000.0 in Q4 2024, little changed YoY from $2000.0 in Q1 2024, and down 71.43% on a QoQ basis from $7000.0 in Q3 2024.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Operating Leases (2023 - 2024) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 2 years of Operating Leases data on file, last reported at $2000.0 in Q4 2024.
- Quarterly Operating Leases changed 0.0% year-over-year to $2000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $2000.0, changed 0.0% from the prior year.
- Operating Leases fell to $2000.0 in Q4 2024, from $7000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $17000.0 in Q1 2024 to a low of $2000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 7,000.00 |